
Simone Romagnoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/356208/publications.pdf Version: 2024-02-01



SIMONE ROMACNOLL

#	Article	IF	CITATIONS
1	<i>ASXL1</i> mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. Blood Advances, 2022, 6, 2927-2931.	5.2	20
2	A blood drop through the pore: nanopore sequencing in hematology. Trends in Genetics, 2022, 38, 572-586.	6.7	2
3	<i>SF3B1</i> mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates. American Journal of Hematology, 2022, 97, .	4.1	9
4	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, <i>CALR</i> -mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	5.2	12
5	Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. Biomarker Research, 2021, 9, 83.	6.8	1
6	RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Advances, 2020, 4, 3677-3687.	5.2	51
7	Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. Cell Reports, 2019, 28, 104-118.e8.	6.4	67
8	Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clinical Chemistry, 2019, 65, 1605-1608.	3.2	4
9	Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs). Blood, 2019, 134, 2968-2968.	1.4	4
10	Large Genomic Alterations Occurring in the Transition from Chronic to Blast Phase of Chronic Myeloproliferative Neoplasms. Blood, 2018, 132, 3028-3028.	1.4	0